Werewolf Therapeutics (HOWL) Net Equity Issued and Repurchased (2020 - 2025)

Werewolf Therapeutics has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $2.3 million in Q4 2025.

• Net Equity Issued and Repurchased for Q4 2025 came in at $2.3 million, down 6.57% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.9 million (down 74.81% YoY), and the FY2025 annual result was $5.9 million, down 74.81% from the prior year.
• Net Equity Issued and Repurchased retreated to $2.3 million in Q4 2025, from $3.3 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $20.2 million in Q1 2024 and troughed at -$29000.0 in Q3 2024.
• A 4-year average of $4.5 million and a median of $2.4 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The widest annual swing landed in 2024, when Net Equity Issued and Repurchased plunged 174.36%; it then soared 11389.66% in 2025.
• A 4-year view of Net Equity Issued and Repurchased shows it stood at $979000.0 in 2022, then jumped by 821.86% to $9.0 million in 2023, then sank by 72.51% to $2.5 million in 2024, then decreased by 6.57% to $2.3 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $2.3 million in Q4 2025, $3.3 million in Q3 2025, and $347000.0 in Q2 2025.